

substrate AI

C/ María de Molina, 41 – Oficina nº 506
28006 Madrid

BME - GROWTH

Palacio de la Bolsa
Plaza de la Lealtad, 1
28014 Madrid

Madrid, 2 August 2023

COMMUNICATION- PRIVILEGED INFORMATION - SUBSTRATE ARTIFICIAL INTELLIGENCE, S.A.

Pursuant to the provisions of Article 17 of Regulation (EU) No 596/2014 on market abuse and Article 228 of Law 6/2023, of 17 March, on Securities Markets and Investment Services, and concordant provisions, as well as BME Growth Circular 3/2020 of BME MTF Equity, we inform you of the following information regarding **SUBSTRATE ARTIFICIAL INTELLIGENCE, S.A. (hereinafter ("Substrate AI" or "the Company" indistinctly)).**

PRIVILEGED INFORMATION - ACQUISITION OF PRODUCTIVE UNIT HOSPITAL EQUIPMENT

Substrate AI, on August 1, 2023, has formalized the acquisition of 100% of the production unit called Equipos Hospitalarios.

Equipos Hospitalarios sells all types of medical equipment for hospitals and veterinary clinics and has a consolidated client portfolio and presence throughout Spain, assuming a perfect platform for the market of diagnostic imaging software solutions that Substrate AI is developing and therefore represents another step in Substrate AI's commitment to the health sector.

Equipos Hospitalarios will be integrated into the company Diagximag, S.L. 100% owned by Substrate AI and will continue to be managed by its current team.

We estimate that Hospital Equipment will contribute to Substrate AI in the first 12 months more than FIVE HUNDRED THOUSAND EUROS (€ 500,000) of income and an ebitda of more than FORTY THOUSAND EUROS (€ 40,000)

The acquisition price has been set at TWO MILLION SIX HUNDRED THOUSAND EUROS (€ 2,600,000) and is paid entirely in shares through capital increases under the compensation formula of credits provided

substrate **AI**

C/ María de Molina, 41 – Oficina nº 506
28006 Madrid

for in article 310 et seq. of Royal Legislative Decree 1/2010 to be approved by the shareholders' meeting as soon as it is convened. Additionally, the purchase agreement includes the obligation to pay an additional amount to the sellers whose calculation is linked to the turnover of the production unit and the profitability of a certain contract.

In compliance with the provisions of Circular 3/2020 of the BME Growth segment of BME MTF Equity, it is expressly stated that the information communicated herein has been prepared under the sole responsibility of the Company and its administrators.

We remain at your disposal for as many clarifications as you consider appropriate.

Kind regards

Lorenzo Serratosa Gallardo

President